Janet Stewart is a life sciences writer and editor, who completed both PhD course work and oral examinations in the Department of Microbiology and Immunology at McGill University, and holds an M.Sc. in Virology and Immunology.
Eisai and Biogen had hoped that using an advanced statistical method to analyze Phase 2 clinical trial results would show at 12 months rather than the normal 18 that their Alzheimer’s therapy ... Read more
Certain variations found in genes that correlate with intelligence and may affect “cognitive reserve” are evident in people with higher levels of education and appear to work to protect against Alzheimer’s ... Read more
Alzheimer’s patients who take benzodiazepines for anxiety, agitation, and insomnia are at a 40 percent greater risk of death than those who don’t take the therapies, a study reports. The research, ... Read more
Biogen and Eisai have deepened their partnership by agreeing to work together on the continued development of the Alzheimer’s therapy aducanumab (BIIB037), which targets harmful beta amyloid protein clusters. The U.S. ... Read more
Scientists are coming closer to understanding how the gene variant apolipoprotein E4 (ApoE4) raises the risk of Alzheimer’s disease. Blocking ApoE4 — one of several variants of the ApoE gene — ... Read more
The use of antidepressants in patients with Alzheimer’s disease increased their risk of head injuries, a Finnish study recently found. The risk of head injuries in these patients previously had ... Read more
E-Scape Bio, the Gladstone Institutes’ spin-off company working to develop therapies for neurodegenerative disorders such as Alzheimer’s disease, announced that it has raised a total of $63 million in Series A financing ... Read more